Last updated 2026-07-20
- Acquired by Purple Biotech for $100M, Feb 2023
- Raised Series B, Jan 2020
- Raised Series A, Mar 2019
Total raised
—
Last: Undisclosed Round 2020-02
Stage
Acquired
Founded
2018
Headcount
5
HQ
Yavne, Israel
Sector
Health Tech & Life Sciences
About
Immunorizon developed a bi-specific T-cell engager with dramatically reduced toxicity, having long serum half-life, while maintaining improved tumor penetration. The company's platform maintains healthy tumor penetration in the human body, enabling physicians to protect patients' bodies from the harmful effects of toxicity. Immunorizon is developing conditionally activated Tumor-Restricted T- and NK-Cell Engagers for cancer therapy, extending its pipeline by using tri-specific constructs with additional tumor-associated antigens and diverse engagers with both T-cells and NK-cells.
Funding history · 3 rounds · — total
2020-01
B Round
Undisclosed
2019-03
A Round
Undisclosed
2017-11
Seed
Undisclosed
★ ExploreBio
Q&A
- What is Immunorizon's primary focus?
- Immunorizon is developing conditionally activated tumor-restricted T- and NK-cell engagers for cancer therapy, extending its pipeline with tri-specific constructs and diverse engagers for both T-cells and NK-cells.
- When was Immunorizon founded?
- Immunorizon was founded in December 2017.
- What is Immunorizon's current status?
- Immunorizon was acquired by Purple Biotech in February 2023.
- Who acquired Immunorizon and for how much?
- Immunorizon was acquired by Purple Biotech in February 2023 for $100,000,000.
- How many employees does Immunorizon have?
- Immunorizon has 1-10 employees.
- Who are the key executives at Immunorizon?
- Oren Bogin serves as CEO and Liat Dassa is the VP R&D at Immunorizon.
- Which investors participated in Immunorizon's funding rounds?
- Immunorizon received investment from M Ventures and ExploreBio.
- What is Immunorizon's primary sector?
- Immunorizon's primary sector is Health Tech & Life Sciences, specifically focusing on Pharma & Medical Biotechnology and Drugs Discovery & Development.
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsCells
Business model
B2B
Tags
cancer-therapyimmunologyoncologyantibodiesbiotechnology
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | www.explorebio1.com |
|---|
Identifiers & details
| Legal name | Immunorizon Ltd. |
|---|---|
| Former names | ExploreBio1 |
| Founded | 2018-2 |
| Employees (exact) | 5 |
| Status reason | Acquired by Purple Biotech on Feb, 2023 |
Acquisitions & public offerings
Acquired by Purple Biotech 2023-02 $100.0M
Radar intelligence
Patents
| EPO | 5 |
|---|
Israeli Companies Registrar (רשם החברות / ICA)
| Registrar # (ח.פ.) | 515756047 |
|---|---|
| Status | פעילה |
| Corp type | ישראלית חברה פרטית |
| Incorporated | 2017-12-14 |
| Purpose | לעסוק בכל עיסוק חוקי |
| Liability | מוגבלת |
| In violation (unfiled) | yes |
| Last annual report | 2022 |
| Active charges / liens | 0 |
| Registry events | 0 |
| Registered address | הקישון 18 יבנה |